Patient satisfaction with ExtaviPro™ 30G, a new auto-injector for administering interferon β-1b in multiple sclerosis: results from a real-world, observational EXCHANGE study

BACKGROUND: Patients with multiple sclerosis (MS) receiving long-term, subcutaneous interferon β-1b (IFN β-1b; Extavia®) often experience injection-site reactions and injection-site pain, which together with other side-effects (such as flu-like symptoms) result in suboptimal treatment compliance/adh...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoffmann, Frank A., Trenova, Anastasiya, Llaneza, Miguel A., Fischer, Johannes, Lus, Giacomo, von Bredow, Dorothea, Lara, Núria, Lam, Elaine, Van Hoef, Marlies, Bakshi, Rajesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5549369/
https://www.ncbi.nlm.nih.gov/pubmed/28793876
http://dx.doi.org/10.1186/s12883-017-0928-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5549369/
https://www.ncbi.nlm.nih.gov/pubmed/28793876
http://dx.doi.org/10.1186/s12883-017-0928-9

Ejemplares similares